Yun Fan

2.8k total citations · 1 hit paper
102 papers, 1.5k citations indexed

About

Yun Fan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yun Fan has authored 102 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 27 papers in Molecular Biology. Recurrent topics in Yun Fan's work include Lung Cancer Treatments and Mutations (56 papers), Lung Cancer Research Studies (41 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Yun Fan is often cited by papers focused on Lung Cancer Treatments and Mutations (56 papers), Lung Cancer Research Studies (41 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Yun Fan collaborates with scholars based in China, United States and Spain. Yun Fan's co-authors include Zhiyu Huang, Jun‐Fang Lin, Kaiyan Chen, Li‐Qiong Guo, Zhiwei Ye, Bai‐Xiong Chen, Yanjun Xu, Xiaoqing Yu, Qianwang Zheng and Tao Wei and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Yun Fan

97 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

2024 56 citations Yun Fan, Dingzhi Huang et al. Journal of Thoracic Oncology profile →

Peers

Yun Fan

ONCOL

PRM

PHARM

PFM

Jun Ho Yi South Korea

Xiaoping Qian China

Armida D’Incecco Italy

Matthew D Westfall United States

Rishil J. Kathawala United States

Elena Tourkina United States

Agrin Moeini Spain

Neelu Puri United States

Ezia Bello Italy

Jianwen Cheng China

Jun Ho Yi South Korea

Yun Fan

552 ×0.6

ONCOL

214 ×0.4

PRM

514 ×1.0

56 ×0.3

PHARM

217 ×1.1

PFM

Citations per year, relative to Yun Fan Yun Fan (= 1×) peers Jun Ho Yi

Countries citing papers authored by Yun Fan

Since Specialization

Citations

This map shows the geographic impact of Yun Fan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yun Fan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yun Fan more than expected).

Fields of papers citing papers by Yun Fan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yun Fan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yun Fan. The network helps show where Yun Fan may publish in the future.

Co-authorship network of co-authors of Yun Fan

This figure shows the co-authorship network connecting the top 25 collaborators of Yun Fan. A scholar is included among the top collaborators of Yun Fan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yun Fan. Yun Fan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Gen, Yongsheng Wang, Tao Xin, et al.. (2025). Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer. Thoracic Cancer. 16(11). e70088–e70088.

Chen, Huajun, Hai‐Yan Tu, Yanping Hu, et al.. (2025). A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001). Journal of Hematology & Oncology. 18(1). 3–3. 3 indexed citations

Chen, Yunfei, Zhiyu Huang, Yanjun Xu, et al.. (2024). Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis. Lung Cancer. 188. 107475–107475. 3 indexed citations

Chen, Ning, et al.. (2023). Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study. Thoracic Cancer. 15(2). 122–130. 2 indexed citations

Fan, Yun, Yao Zhao, Dabing Huang, et al.. (2023). OA01.06 First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study. Journal of Thoracic Oncology. 18(11). S46–S46. 14 indexed citations

Chen, Kaiyan, Yanjun Xu, Zhiyu Huang, et al.. (2023). Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial. Cancer Medicine. 12(19). 19460–19470. 10 indexed citations

Zhou, Qing, Jun Zhao, Jianhua Chang, et al.. (2023). Efficacy and safety of pralsetinib in patients with advanced RET fusion‐positive non–small cell lung cancer. Cancer. 129(20). 3239–3251. 14 indexed citations

Lü, Shun, Jian Fang, Ziping Wang, et al.. (2022). Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer. Cancer Medicine. 12(3). 2666–2676. 6 indexed citations

Li, Hui, Yongchang Zhang, Yanjun Xu, et al.. (2022). Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer. Cell Death and Disease. 13(12). 1064–1064. 14 indexed citations

10.

Li, Hui, Xiaoqing Yu, Kaiyan Chen, et al.. (2021). Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China. Thoracic Cancer. 12(22). 3019–3031. 20 indexed citations

11.

Zhou, Caicun, Lin Wu, Yun Fan, et al.. (2020). LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC). Annals of Oncology. 31. S1186–S1186. 14 indexed citations

12.

Xu, Xiaoling, et al.. (2020). Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma. Frontiers in Oncology. 10. 544789–544789. 10 indexed citations

13.

He, Baolin, Qianwang Zheng, Li‐Qiong Guo, et al.. (2019). Structural characterization and immune-enhancing activity of a novel high-molecular-weight polysaccharide from Cordyceps militaris. International Journal of Biological Macromolecules. 145. 11–20. 83 indexed citations

14.

Yu, Xin & Yun Fan. (2019). P1.01-100 Effect of Osimertinib in Non-Small Cell Lung Cancer Patients with Brain Metastases After Progression Following Front-Line EGFR-TKI Therapy. Journal of Thoracic Oncology. 14(10). S400–S400. 1 indexed citations

15.

Zou, Yuan, Qianwang Zheng, Li‐Qiong Guo, et al.. (2019). Purification and structural characterization of a novel natural pigment: cordycepene from edible and medicinal mushroom Cordyceps militaris. Applied Microbiology and Biotechnology. 103(19). 7943–7952. 15 indexed citations

16.

Fan, Yun, Lei Gong, Hongyang Lu, et al.. (2017). P3.02b-079 Effects of Icotinib with and without Radiation Therapy on Patients with EGFR Mutant Non-Small Cell Lung Cancer and Brain Metastases. Journal of Thoracic Oncology. 12(1). S1238–S1238. 1 indexed citations

17.

Lin, Junfang, et al.. (2016). Construction of Flammulina velutipes genome editing vector by using CRISPR/Cas9 system. 37(20). 234. 3 indexed citations

18.

Shi, Yue, Mei Dong, Xiaoting Hong, et al.. (2015). Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Annals of Oncology. 26(8). 1766–1771. 263 indexed citations

19.

Zhao, Hongyun, Yun Fan, Shenglin Ma, et al.. (2015). Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804). Journal of Thoracic Oncology. 10(4). 655–664. 31 indexed citations

20.

Fan, Yun, Binghe Xu, Peng Yuan, et al.. (2012). Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology. 24(5). 1219–1225. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact